This experiment validates seed amplification assays (SAAs) for early detection of alpha-synuclein pathology in Parkinson's disease, aiming to establish reproducible protocols for clinical diagnostics.
Primary Hypothesis: Alpha-synuclein SAAs will detect pathological aggregates in cerebrospinal fluid (CSF) from patients with early Parkinson's disease with >85% sensitivity and >95% specificity.
Secondary Hypothesis: SAA positivity will correlate with clinical disease severity and predict progression.
Alpha-synuclein aggregation is the hallmark pathology of Parkinson's disease and related synucleinopathies. Current diagnostic criteria rely on clinical features, which lack sensitivity for early detection. Seed amplification assays (also known as RT-QuIC) can detect minute quantities of pathological protein aggregates.
This experiment addresses critical needs:
- Early diagnosis before motor symptoms
- Disease stratification (PD vs. DLB vs. MSA)
- Biomarker for clinical trial enrollment
- Monitoring disease progression
- Parkinson's Disease: n=150 (Hoehn & Yahr stage 1-3)
- Prodromal PD: n=50 (REM sleep behavior disorder without parkinsonism)
- Healthy Controls: n=100 age-matched
- Disease Controls: n=50 (Alzheimer's, essential tremor)
- Validation Cohort: n=100 (independent center)
- Lumbar puncture performed at baseline
- CSF collected in polypropylene tubes
- Centrifuged within 1 hour (2000 × g, 10 min, 4°C)
- Aliquoted and stored at -80°C
- Batch analysis to minimize inter-assay variation
- Recombinant alpha-synuclein monomer prepared (purified from E. coli)
- 40 μL reaction mixture containing:
- 0.1 mg/mL alpha-synuclein
- 10 mM phosphate buffer (pH 8.0)
- 100 mM NaCl
- Add 5 μL CSF sample
- Incubation at 37°C with intermittent shaking
- Thioflavin T fluorescence read every 15 minutes for 100 hours
- Positive: fluorescence > baseline + 3 SD
- Primary: Sensitivity and specificity for early PD detection
- Secondary:
- Correlation with MDS-UPDRS scores
- SAA signal kinetics (lag time, growth rate)
- Longitudinal stability (12-month follow-up)
- Comparison with other biomarkers (neurofilament light chain)
¶ Reagents and Equipment
| Item |
Supplier |
Cost (USD) |
| Recombinant alpha-synuclein |
rPeptide |
$8,000 |
| Thioflavin T |
Sigma |
$300 |
| 96-well plate (black) |
Corning |
$500 |
| Fluorescence plate reader |
BioTek |
$80/hour |
| CSF collection kits |
MD Biosciences |
$3,000 |
| Ultra centrifuge |
Beckman |
$150/hour |
| Western blot supplies |
Bio-Rad |
$2,000 |
Estimated Total Cost: $85,000
- University of Pennsylvania — Dr. Virginia Lee's group (SAA development)
- University of Queensland — Dr. Andrew Hill's group (prion-like propagation)
- Michael J. Fox Foundation — LCI consortium (standardization)
- Karolinska Institutet — Dr. Per Svenningsson's group (clinical cohorts)
- Months 1-3: Sample collection and SAA protocol optimization
- Months 4-6: Primary analysis of all samples
- Months 7-8: Validation cohort analysis
- Months 9-10: Statistical analysis and correlation with clinical data
- Month 11-12: Manuscript and assay standardization protocol
Total Duration: 12 months
- Sensitivity for early PD: >85%
- Specificity vs. healthy controls: >95%
- Specificity vs. Alzheimer's: >90%
- Strong correlation between SAA positivity and motor severity
- SAA kinetics predict faster progression
- Assay reproducible across laboratories (inter-lab CV <15%)
- Standardized protocol with detailed SOPs
- Blinded analysis of all samples
- Pre-registration of analysis plan
- Independent validation cohort
| Dimension |
Score (1-10) |
Rationale |
| Scientific Value |
9 |
Enables early diagnosis and disease understanding |
| Feasibility |
9 |
Established SAA technology, available cohorts |
| Novelty |
8 |
First large-scale multi-center validation |
| Disease Impact |
10 |
Transformative for PD diagnostics and clinical trials |
| Reach |
8 |
Applicable to all synucleinopathies |
| Cost Efficiency |
9 |
Low cost per sample, high impact |
| Time Efficiency |
9 |
12-month timeline is fast for diagnostic validation |
| Evidence Base |
8 |
Promising pilot data from multiple groups |
| Addresses Uncertainty |
9 |
Resolves questions about clinical utility |
| Translation Potential |
10 |
Direct path to clinical diagnostic |
Total Score: 89 × weight normalization = 89/120